Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655399 | 0.82 | HCRTR1 (0.43) | NPC1LMNAPOLBRAB9AGAA | |
| SCHEMBL29604747 | 0.81 | BRD4 (0.55) | NPC1LMNAUSP2KDM4ERAB9A | |
| SCHEMBL1514835 | 0.81 | BRD4 (0.55) | NPC1LMNAUSP2KDM4ERAB9A | |
| SCHEMBL29852549 | 0.81 | ABCB1 (0.50) | NPC1LMNAUSP2KDM4ERAB9A | |
| SCHEMBL4718408 | 0.80 | USP2 (0.49) | NPC1LMNAUSP2KDM4ERAB9A | |
| SCHEMBL18301087 | 0.80 | USP2 (0.51) | CXCR1CXCR2NPC1LMNAUSP2 | |
| SCHEMBL23331253 | 0.77 | USP2 (0.54) | NPC1LMNAUSP2KDM4ERAB9A | |
| SCHEMBL5658061 | 0.75 | RAB9A (0.49) | NPC1LMNAPOLBKDM4ERAB9A | |
| SCHEMBL1969238 | 0.74 | USP2 (0.51) | NPC1LMNAUSP2KDM4ERAB9A | |
| SCHEMBL30454309 | 0.74 | USP2 (0.51) | NPC1LMNAUSP2KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | disclosed |
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-20030139462-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2003-07-24 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| EP-1025102-A1 | BICYCLIC KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | CXCR1 626/4885CXCR2 425/4885NPC1 930/4885 |
| US-20030139462-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | CXCR1 626/4885CXCR2 425/4885NPC1 930/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | CXCR1 626/4885CXCR2 425/4885NPC1 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.